Michel Julien

Michel Julien is a seasoned biotechnology professional with extensive experience in the field of Chemistry, Manufacturing, and Controls (CMC). Currently serving as Director CMC at NH TherAguix since November 2020, Michel oversees the CMC strategy for the development of the lead drug candidate AGuIX. Previous roles include Senior Director CMC and Director CMC at MILLENDO THERAPEUTICS, where significant responsibilities involved managing various contract manufacturing organizations (CMOs) and validating manufacturing processes for drug products. Earlier positions at Alizé Pharma, Transgene, Opsona Therapeutics, and Avidis SA showcased expertise in biopharmaceutical development, project leadership, and team management, including the development and analysis of proteins and membranes. Michel holds a PhD in Biochemistry from Université Paul Sabatier Toulouse III.